Indocyanine green
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1959
- First approval year
- 1959
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Indocyanine green
- Molecular weight
- 774.98
- Structure (SMILES)
- CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)[O-])c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)[O-])c2ccc3ccccc3c21.[Na+]
- ic green
- Ic-green
- indocyanine green
- Indocyanine green
- spy agent green kit
- Spy agent green kit
- 1h benz e indolium 2 7 1 3 dihydro 1 1 dimethyl 3 4 sulfobutyl 2h benz e indol 2 ylidene 1 3 5 heptatrienyl 1 1 dimethyl 3 4 sulfobutyl hydroxide inner salt sodium salt
- 1H-BENZ(E)INDOLIUM, 2-(7-(1,3-DIHYDRO-1,1-DIMETHYL-3-(4-SULFOBUTYL)-2H-BENZ(E)INDOL-2-YLIDENE)-1,3,5-HEPTATRIENYL)-1,1-DIMETHYL-3-(4-SULFOBUTYL)-, HYDROXIDE, INNER SALT, SODIUM SALT
- 2 7 1 1 dimethyl 3 4 sulfobutyl benz e indolin 2 ylidene 1 3 5 heptatrienyl 1 1 dimethyl 3 4 sulfobutyl 1h benz e indolium hydroxide inner salt sodium salt
- 2-[7-[1,1-Dimethyl-3-(4-sulfobutyl)benz[E]indolin-2-ylidene]-1,3,5-heptatrienyl]-1,1-dimethyl-3-(4-sulfobutyl)-1H-benz[E]indolium hydroxide, inner salt, sodium salt
- ic green
- IC Green
- IC-Green (ICG)
- ICG (Indocyanine Green)
- indocyanine green
- Indocyanine green
- Indocyanine Green
- Indocyanine Green (IC-Green)
- indocyanine green (ICG)
- Indocyanine green (ICG)
- Indocyanine Green (ICG)
- Indocyanine Green (ICG)-Assisted Ureteral Identification
- INDOCYANINE GREEN [HSDB]
- INDOCYANINE GREEN [JAN]
- INDOCYANINE GREEN [MART.]
- INDOCYANINE GREEN [MI]
- INDOCYANINE GREEN [ORANGE BOOK]
- INDOCYANINE GREEN [USP MONOGRAPH]
- INDOCYANINE GREEN [USP-RS]
- INDOCYANINE GREEN [VANDF]
- Indocyanine green [WHO-DD]
And 31 more, listed on the interactive page.
- ATC classification codes
- V04CX01
Sources for recorded values
- CAS registry numbers
- 3599-32-4
- ChEMBL ID
- CHEMBL1646
- InChIKey
- MOFVSTNWEDAEEK-UHFFFAOYSA-M
- RxNorm IDs (RxCUI)
- 5775
- FDA ingredient codes (UNII)
- IX6J1063HV
- 19190
- 5282412
- 5284572
- 11967809
- 43835846
- 45101199
- 51063122
- 58606996
- 74764374
- 92132757
- 132274068
- 156599054
- 165411817
- 169410069
- Applicant
- PROVEPHARM SAS
- Approval date
- 10 Jul 2026
- Application number
- NDA218579
- Patents
- 5
- Designations
- 0
- Earliest recorded loss of exclusivity
- 14 Jul 2039
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Pharmacology name
- indocyanine green
- Type
- Synthetic organic
Administration routes
- Parenteral
Mechanisms of action
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- OATP1B1
- Gene symbol
- SLCO1B1
- Protein identifier
- Q9Y6L6
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Breast Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000305
- Subject identifier
- D001943
- Condition
- Melanoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000389
- Subject identifier
- D008545
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000503
- Subject identifier
- D013274
- Condition
- Wounds and Injuries
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000546
- Subject identifier
- D014947
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Periodontitis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000649
- Subject identifier
- D010518
- Condition
- Carcinoma, Renal Cell
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000681
- Subject identifier
- D002292
- Condition
- Arthritis, Rheumatoid
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000685
- Subject identifier
- D001172
- Condition
- Sarcoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000691
- Subject identifier
- D012509
- Condition
- Uterine Cervical Neoplasms
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0001061
- Subject identifier
- D002583
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Bone Neoplasms
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0003820
- Subject identifier
- D001859
- Condition
- Brain Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003833
- Subject identifier
- D001932
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003897
- Subject identifier
- D013274
- Condition
- Head and Neck Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0006859
- Subject identifier
- D006258
- Condition
- Endometrial Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007532
- Subject identifier
- D016889
- Condition
- Retinal Perforations
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001028
- Subject identifier
- D012167
- Condition
- Rotator Cuff Injuries
- Highest recorded phase
- 1
- Condition identifier
- EFO:1001250
- Subject identifier
- D000070636
- Condition
- Endometrial Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001512
- Subject identifier
- D016889
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0001056
- Subject identifier
- D013274
- Condition
- Head and Neck Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0002038
- Subject identifier
- D006258
- Condition
- Periodontal Diseases
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0002635
- Subject identifier
- D010510
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005575
- Subject identifier
- D015179
- Condition
- Breast Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
And 6 more, listed on the interactive page.
- Condition identifier
- EFO_0000546
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000649
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000681
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000685
- Highest recorded phase
- 1
- Condition identifier
- EFO_0001061
- Condition identifier
- EFO_0003060
- Condition identifier
- EFO_0003820
- Condition identifier
- EFO_0003833
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003897
- Highest recorded phase
- 3
- Condition identifier
- EFO_0006859
- Condition identifier
- EFO_0007176
- Condition identifier
- EFO_0009527
- Condition identifier
- EFO_0010282
- Condition identifier
- EFO_0010282
- Highest recorded phase
- 4
- Condition identifier
- EFO_1000453
- Condition identifier
- EFO_1000657
- Condition identifier
- EFO_1001250
- Highest recorded phase
- 1
- Condition identifier
- EFO_1001390
- Highest recorded phase
- 1
- Condition identifier
- EFO_1001480
- Condition identifier
- EFO_1001512
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0001528
- Condition identifier
- MONDO_0002038
- Condition identifier
- MONDO_0002635
- Highest recorded phase
- 3
And 17 more, listed on the interactive page.
- Event
- age-related macular degeneration
- Reports
- 2
- Reporting signal score
- 10.2436
- Event
- anaphylactic shock
- Reports
- 5
- Reporting signal score
- 16.201
- Event
- contrast media allergy
- Reports
- 3
- Reporting signal score
- 16.5352
- Event
- haemangioma congenital
- Reports
- 8
- Reporting signal score
- 58.2164
- Event
- low birth weight baby
- Reports
- 8
- Reporting signal score
- 37.7889
- Event
- optic nerve disorder
- Reports
- 2
- Reporting signal score
- 10.7887
- Event
- patent ductus arteriosus
- Reports
- 8
- Reporting signal score
- 43.0468
- Event
- product label issue
- Reports
- 2
- Reporting signal score
- 9.50693
- Event
- retinal injury
- Reports
- 2
- Reporting signal score
- 11.9542
- Event
- retinal scar
- Reports
- 2
- Reporting signal score
- 12.7775
- NCT00453050
- NCT00540982
- NCT01083004
- NCT01095913
- NCT02027818
- NCT02462200
- NCT02473159
- NCT02479997
- NCT02817334
- NCT06327490
- NCT01281488
- NCT01335893
- NCT05346380
- NCT02043340
- NCT02570815
- NCT02570958
- NCT02598219
- NCT02680067
- NCT04046146
- NCT05197530
- NCT02949726
- NCT03050879
- NCT03262636
- NCT03557827
- NCT03745690
And 21 more, listed on the interactive page.
- Dose
- 1.25 mg to 5 mg
- Route
- Intravenous
- How often
- As needed
Conditions of use
- Immediately flush with 10 mL of 0.9% Sodium Chloride Injection
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 1
- Polar surface area
- 117.82
- Calculated partition coefficient (ALogP)
- 8.71
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 14
- Heavy atoms
- 54
- Molecular formula
- C43H47N2NaO6S2
- Monoisotopic mass
- 774.27732385
- Natural product
- No
- 25021-841
- Recorded assays
- 456
- Active assays
- 50
- Confirmatory
- Other
- Screening
- Coloring Agents
Related records
Trials (269)
- 3D Printing for Nodule Localization
- A French Observational Study of Indocyanine Green for Patients With Breast Cancer Having a Sentinel Lymph Node Biopsy.
- A Multimodality Image-guided System for Peripheral Lung Cancer Diagnosis and Therapy
- A Pilot Study of Optical Molecular Imaging for Percutaneous Biopsy of Hepatocellular Carcinoma Using Indocyanine Green
- A Prospective Clinical Study for Evaluation of Safe Resection Margin in Breast Conserving Surgery in Breast Cancer
- A PROSPECTIVE, SINGLE-CENTERED, ASSESSOR-BLINDED STUDY TO EVALUATE THE CLINICAL EFFICACY OF THE PROPOSED CELL/TISSUE HISTOPATHOLOGY PROCESSOR CCELL (CONFOCAL FLUORESCENCE ENDOMICROSCOPY) FOR INTRAOPERATIVE DIAGNOSIS IN BRAIN TUMORS
- A Randomized Controlled Trial to Improve the Therapeutic Effect of Robot-assisted Radical Prostatectomy (RARP) Using Indocyanine Green Fluorescence Imaging
- A Study Comparing Green Fluorescent Dye and Radioactive Dye for Sentinel Lymph Node Biopsy in Pediatric Cancers
- A Study Evaluating the Feasibility and Compliance of Manual Lymphatic Drainage Comparing Indocyanine-Green (ICG) Guided vs. Traditional Guided in Patients Undergoing Axillary Node Dissection for the Treatment of Breast Cancer
- A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDT
- A Study to Evaluate Indocyanine Green Lymphangiography to Improve Lymphadenectomy in Gastric Cancer Patients
- Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Giant Cell Tumor of Bone Surgery
- Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Tenosynovial Giant Cell Tumor Surgery
- Accuracy of Sentinel Lymph Node Biopsy in Nodal Staging of High Risk Endometrial Cancer
- Advanced Gastrointestinal Endoscopic Imaging
- Angiosome Perfusion After Tibial Bypass
- Antimicrobial Photodynamic Therapy in Chronic Periodontitis and Diabetes Mellitus
- Application of ICG in Lymph Node Dissection During Radical Resection of Rectal Cancer With Preserved Autonomic Nerves Around LCA and IMA
- Application of Indocyanine Green Angiography for Closed Operative Calcaneus Fractures
- Application of Surgical Navigation System in Sentinel Lymph Node of Breast Cancer Research
In development for (31)
- Bone neoplasm Early phase 1
- Brain neoplasm Phase 1
- Breast cancer Phase 2
- Breast carcinoma Phase 2
- Cervical carcinoma Early phase 1
- Colorectal cancer Phase 3
- Cutaneous melanoma Phase 1
- Endometrial cancer Phase 3
- Endometrial carcinoma Phase 3
- Gastric adenocarcinoma Phase 3
- Gastric cancer Phase 3
- Gastric neoplasm Phase 3
- Head and neck cancer Phase 2
- Head and neck carcinoma Phase 2
- Hepatocellular carcinoma Phase 1
- Injury Phase 2
- Lung cancer Phase 1
- Lung neoplasm Phase 1
- Lymphedema Phase 1
- Macular holes Phase 3
Other linked conditions (6)
- Bone giant cell tumor
- Cervical cancer
- Liver cancer
- Paraganglioma
- Rectal cancer
- Vulva cancer